Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vera Therapeutics, Inc. - Class A Common Stock
(NQ:
VERA
)
29.79
-0.36 (-1.18%)
Delayed Quote
Updated: 4:00 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vera Therapeutics, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
Next >
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 06, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
November 05, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
November 02, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
October 22, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
October 20, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
October 02, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
September 15, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate at Upcoming Investor Conferences
September 01, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
August 10, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
July 09, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
July 07, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
June 02, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 08, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 07, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
May 04, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 10, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 27, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
March 25, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Appoints Christopher Hite to Board of Directors
March 05, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
February 26, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate at Upcoming Investor Conferences
February 24, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
January 28, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 08, 2026
From
Vera Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
